We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/48155>

1.1. The peritoneal cavity, locoregional area

The diagram illustrates the pathways of peritoneal dissemination of gastric cancer cells. It shows a cross-section of the stomach wall layers: Mucous membrane, Submucosa, Muscular layer, and Subserous layer. A Primary tumor is shown in the mucosa. Two main pathways are labeled A and B. Pathway A shows cells (1) detaching from the tumor, becoming abdominal free cancer cells (2), and then implanting on the peritoneal cavity (3). Pathway B shows cells (1) invading the subserous layer (2) and then entering the submesothelial lymphatic space (3') to reach the lymphatic orifice on milky spots (3''). Both pathways lead to the subperitoneal tissue (4), where cells (5) can implant and form secondary tumors (6). The diagram also indicates the Stomach wall, Peritoneal cavity, Subperitoneal tissue, and Blood-peritoneal barrier.

Any pathological process involving the peritoneal cavity can easily disseminate throughout this space by means of unrestricted movement of fluid and cells. Accordingly malignant

intraperitoneal tumour progression, before reaching the circulation system and developing distant metastases (pulmonary, brain and bone metastases) diffuses within and through the peritoneal cavity (Fig. 1). At this step intraperitoneal tumours must be considered in locoregional stage.

Peritoneal neoplasia can originate de novo from the peritoneal tissues (primary tumour) or invade or metastasize into the peritoneum from adjacent or remote organs (metastases).

Rare are the primitive tumours of the peritoneum: they include malignant mesothelioma, peritoneal primary carcinoma and sarcoma.

Malignant peritoneal mesothelioma is a rare but aggressive tumor derived from the peritoneal mesothelium accounting for 2 cases per 1 million population reported each year in USA. Association of malignant peritoneal mesothelioma and asbestos exposure has been reported to be as high as 83%. This locally aggressive disease is difficult to treat or palliate. Commonly, treatment regimens combine aggressive cytoreductive surgery with intraperitoneal chemotherapy. Cytoreductive surgery is the cornerstone of current treatment, while hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is a promising strategy in suitable patients (Deraco *et al.*, 2002) (Fig. 2).

Figure 2. Omental cake.

Primary peritoneal carcinoma is a very rare tumour and (ie, serous surface papillary carcinoma) arises primarily from peritoneal cells. This malignancy predominantly affects postmenopausal women and typically displays multicentric peritoneal and omental involvement. Pathologically and clinically, it resembles papillary serous ovarian carcinoma.

Many primary tumours, arising from organs placed within the peritoneal cavity, disseminate through it, leading patients to death. Peritoneal cavity represents the site of metastases in 50% of colorectal cancer, 50% of gastric cancer and 75% of ovarian advanced cancer. It represents the sole site of intraperitoneal metastasis in 20-25% of colorectal cancer, 30% of gastric cancer and 70% of ovarian cancer (Koppe *et al.*, 2006; Randall and Rubin, 2001; Sadeghi *et al.*, 2000). Intraperitoneal drug administration studies confirmed the existence of a peritoneal-plasma barrier which allows to concentrate the antitumour drug within the cavity even 100-1000 times compared with that of the same drug infused through systemic circulation. Therefore a high antitumour drug tissue concentration and a low systemic toxicity can be achieved (Flessner, 2005). In association with intraperitoneal chemotherapy, hyperthermia has been demonstrated to enhance drug diffusion within the tumour tissue and also to have a direct antitumour activity (Issels, 2008) (Fig. 3)

Figure 3. Hyperthermia effects on tumour cells.

Therefore cytoreduction and HIPEC procedure have been suggested to treat metastases from colorectal, gastric and gynaecological tumors (Sugarbaker, 1995). Results after treatment are encouraging in particular in cases of colorectal and gynaecological cancer with median 5 years survival respectively of 40% and 45%. Less satisfactory results have been obtained in case of gastric and pancreatic cancer with a minimal percentage of patient still living far from initial diagnosis (Elias *et al.*, 2006; Roviello *et al.*, 2011). The aggressive tumour surgical removal (tumour cytoreduction) coupled with intraperitoneal chemotherapy nowadays represents the cornerstone of advanced abdominal oncologic surgery (Glehen *et al.*, 2006; Glockzin *et al.*, 2009). A large international experience was therefore made through the last decades with the goal of allowing treatment and possibly cure of intraperitoneal tumours in advanced stage (Levine *et al.*, 2007; Roviello *et al.*, 2011).

Figure 4. Peritoneal cancer index to map carcinosis localization.

2. Cytoreduction and intraperitoneal hyperthermic chemotherapy (HIPEC)

Advanced metastatic tumour can therefore be treated with surgery and hyperthermic chemotherapy contemporarily, during the same surgical operating work up. The first step is to carry out an aggressive cytoreduction in order to remove the whole macroscopic intracavitary tumour tissue and then to complete the procedure with HIPEC, to kill residual neoplastic cells floating within the peritoneal cavity or adherent to intraperitoneal tissue.

2.1. Cytoreduction

The surgical procedure of cytoreduction is now well standardized . Sugarbaker’s classification is still the reference for abdominal oncologic surgery and goes under the definition of peritonectomy. The surgical procedure was classified according to specific different areas of the abdominal cavity and it has been tailored by Milan ‘s panel workshop, defining (Fig. 4):

Figure 5. Surgical cytoresduction.

1. Upper Right Peritonectomy: right diaphragmatic peritonectomy with Glisson's capsule dissection; lesser omentectomy, stripping of the omental bursa and cholecystectomy plus gastric antrectomy or total gastrectomy.
2. Upper Left Peritonectomy: left diaphragmatic and parietal peritonectomy with splenectomy and greater omentectomy.
3. Pelvic Peritonectomy: pelvic parietal peritonectomy, sigmoidectomy, hysterectomy and salpingo-ovariectomy.
4. Right Parietal Peritonectomy, right/total colectomy; left parietal peritonectomy.
5. Mesenteric implants on visceral surfaces could be removed surgically or by electrosurgical local dissection. Performing cytoresduction for peritoneal tumour dissemination, not all the procedures are necessary and made, usually necessitating one – three of the different peritonectomy procedures (Fig. 4 and 5).

2.2. Intraperitoneal hyperthermic chemotherapy

After having made complete surgical cytoresduction with an absent or minimal residual disease (less than 2.5 mm tumour diameter) some catheters are inserted into the abdominal cavity and a perfusion of 2 liters of a saline solution with a determined quantity of antitumour drug (Mitomycin, Oxaliplatin for digestive cancer and Cisplatin, Taxol for ovarian cancer) is made. The peritoneal perfusion may last 30-90 minutes and it can be performed in condition of closed abdomen or open abdomen (Coliseum technique) or a compromise between the two, with an abdominal-wall small entrance suitable for the handling by the operator. (Fig. 6).

Figure 6. Hyperthermic intraperitoneal chemotherapy

Hyperthermic perfusion can be obtained by heating the perfusion medium with a heat exchanger connected to the perfusion pump. The peritoneal cavity temperature considered optimal in terms of antitumor activity and antitumour tissue diffusion is 41,5-42,5 °C (Sugarbaker and Chang, 1999; Sugarbaker, 1996; Van der Speeten *et al.*, 2009). It is of absolute importance to control the temperature of organs and bowels during the procedure. Excessive temperature of intraperitoneal tissue, more than 43 °C, is strongly correlated with lesions of the bowel wall and perforation, and also with necrosis of nerves, bladder or vases. To prevent excessive intraperitoneal temperature multiple temperature probes are placed within the peritoneal cavity to monitorate the temperature. At the end of the procedure the perfused medium is usually removed from the peritoneal cavity.

3. Advanced oncological surgery in colorectal cancer

Every year about 400.000 new cases of colorectal cancer (CRC) are diagnosed in Europe and 210.000 are believed to die of disease (Boyle and Ferlay, 2005). Peritoneal carcinosis (PC) has an incidence about 13% of CRC, in 58% of cases is synchronus with primary disease and in most cases is not diffused to the entire abdominal cavity but limited to an area (Jayne *et al.*, 2002). Peritoneal cavity recurrence is the only site of relapse in about 25% of cases (Chu *et al.*, 1989). The principal mechanism of peritoneal cancer diffusion through the abdominal cavity is the esfoliation of cancer cells following bowel-serosa tumour infiltration. Also lymphatic channel infiltration by the tumour followed by breaking of the lymphatic channel wall and subsequently loss of neoplastic cells within the abdominal cavity is a mechanism of PC formation. Furthermore at the time of surgical work up tumour manipulation and blood loss

are also intracavitary mechanism of PC formation. Facing PC, both synchronous or metachronous, the usual treatment is systemic chemotherapy but median survival is usually not longer than 6 months even after the advent of new drugs and treatment scheme (Sadeghi *et al.*, 2000). More recently Dominique Elias has published an experience with patients with PC and absence of extra-abdominal disease by using modern scheme of chemotherapy FOLFOX (5-FU, AF and oxaliplatin) and FOLFIRI (5-FU, AF and irinotecan) obtaining a median survival of 23,9 months and a 2 and 5 years survival of 65% and 13% respectively (Elias *et al.*, 2009). The advent of CRS with HIPEC have ameliorated the prognosis in these patients (Elias *et al.*, 2006; Verwaal *et al.*, 2005; Yan and Morris, 2008).

During the last decade a randomized study , two multicentric comparative studies and a numbers of observational studies have tested the CRS and HIPEC activity against PC from CRC with encouraging results: mortality and postoperative morbidity of 0-8% and 39-72% respectively and 5 years survival of 40-51% (Verwaal *et al.*, 2003, 2005; Elias *et al.*, 2009, 2006; Franko *et al.*, 2010). Main indications for application of the procedure are the presence of PC both synchronous or metachronous , therefore defining it a therapeutic procedure. But recent experiences also suggest the possible use of HIPEC in adjuvant setting after radical surgery work up. Not all patients with CRC could benefits from this approach. A number of risk factors for PC development have been demonstrated: minimal PC which was macroscopically visible, completely resected or ovarian metastasis (also resected), synchronous with the primary tumour or a perforated primary tumor inside the peritoneal cavity, primary CRC presenting with occlusion or haemorrhagia. Patients bearing these risk factors and treated with cytoreduction and HIPEC at the end of cytoreduction (no residual tumour disease was present - R0 resection) showed, in preliminary experiences, impressive results with a 5 years survival percentage reaching 90% and a 5 years disease free survival of more than 40% (Elias *et al.*, 2009). This preliminary experience supports a large number of multi-istitutional ongoing worldwide studies to confirm the role of cytoreduction and hyperthermic intraperitoneal chemoperfusion in adjuvant setting at the same time of primary surgery or after a planned second look exploration. This new therapeutic approach even if after a long maturation phase lasting more than a decade, now seems to be accepted as a new frontier to treat advanced CRC and world wide surgical units have been created to coordinate and carry on the associated medical activity.

4. Advanced oncological surgery in gastric cancer

PC from gastric cancer arises following tumours invasion of the gastric serosa as depicted in Fig. 7. Also histological type can be crucial in PC gastric developing. Gastric tumours of the diffused type seems to represent a risk factor for PC and it has been demonstrated to relapse in about 50% of cases even after curative surgical resection (Marrelli *et al.*, 2002). It has been shown that the serosal tumor invasion is correlated to the detection rate of intraperitoneal free cancer cells. The treatment of peritoneal carcinomatosis from gastric cancer by peritonectomy and HIPEC has demonstrated not so good long-term results when compared with the treatment of PC from other causes (Stewart *et al.*, 2005). Anyway conventional treatment using palliative systemic chemotherapy showed a very dismal prognosis

(Hanazaki *et al.*, 1999). Long survival after peritonectomy and HIPEC for carcinomatosis arising from gastric cancer are possible if the extension of the carcinosis is low and the cytoreduction is complete. 3-year survival of 41% and 5-year survival rates of 11% was reported (Sayag-Beaujard *et al.*, 1999; Yonemura *et al.*, 2001, 1996). CRS and HIPEC of the PC seems to allow longer survival even if hyperthermic intraperitoneal chemoperfusion role is still under evaluation.

Figure 7. Invasion of the gastric serosa.

Recent experiences with HIPEC have shown quite encouraging results in case of prevention of peritoneal recurrence after radical surgery for primary carcinoma, the adjuvant role. When curative gastrectomy is performed, in fact, peritoneal recurrence develops in nearly 50% of patients, therefore prevention of PC developing represent a fundamental goal in this setting (Yonemura *et al.*, 2001, 1996; Fujimoto *et al.*, 1999; Shen *et al.*, 2009). Worldwide experiences are ongoing to ascertain the role of HIPEC in adjuvant setting and definitive results will be available in a short time.

5. Advanced oncological surgery in ovarian cancer

Epithelial ovarian cancers account for 80% to 90% of all ovarian malignancies and are the main cause of death for all gynaecological tumors (Yancik, 1993). Despite being diagnosed frequently at an advanced stage, dissemination is often confined to the peritoneal cavity (Randall and Rubin, 2001). It presents with vague gastrointestinal and constitutional symptoms of abdominal bloating, distension, weight loss, and fatigue (Goff *et al.*, 2000). Late presentation results in the majority of patients being diagnosed with advanced disease (Stage III/IV). The 5-year survival rate of patients with advanced ovarian cancer is <25% (Ozols, 2005). In the final stages of this disease, patients suffer from severe anorexia, dyspnea and pain from malignant bowel obstruction, ascites, and pleural effusion as a result of the extensive burden of tumor.

Epithelial ovarian tumor arises from the serosal lining of the ovary. This covering of the ovary communicates with the serosal lining of the abdominopelvic cavity, and is known as the peritoneum. Tumor growth results in the exfoliation of malignant cells into the peritoneal fluid. They circulate freely and typically implant in the pelvis and subdiaphragmatic recesses owing to gravity and the incumbent position. Intraoperatively, it is characterized by the extensive presence of macroscopic whitish tumor nodules of variable sizes and consistency that may coalesce to form plaques or masses within the abdominopelvic cavity.

Tumor dissemination from the primary tumour may also occur through the lymphatic channel disrupted by the tumour and the direction of neoplastic cell diffusion is all through the abdominal cavity.

CRS using limited peritonectomy procedures to resect peritoneal implants and HIPEC aims to allow both macroscopic cytoreduction through surgery and cytotoxic cytoreduction through loco-regional administration of heated chemotherapy. Cytoreduction and HIPEC has been tested in different routes; front line when treating the primary cancer, as interval surgery after neoadjuvant chemotherapy in case of unresectable cancer, as treatment of ovarian cancer relapses and even in case of salvage therapy (Look *et al.*, 2004).

Figure 8. Ovarian cancer survival in complete and non complete cytoreduction.

The largest experience to date was reported by Bereder who reported a median overall survival of 46 months in patients with first relapsed ovarian cancer of which a proportion are chemoresistant. In their institutions, the mortality rate was under 1% and the morbidity rates were about 10%. The treatment related complications is considered acceptable and further large volume peritonectomy units have low mortality rates that range from 0 to 2% (Raspagliesi *et al.*, 2006; Bereder *et al.*, 2009; Look *et al.*, 2004). Nowadays there is large

agreement on the role of extreme cytoreduction of peritoneal carcinosis in case of ovarian cancer. Two groups of patients are then obtained: those with residual disease no more than 2.5 mm in diameter corresponding to the completeness cytoreduction rate CC0-1 and those with residual disease more than 2.5 mm CC2-3. The first group with a complete tumour eradication shows a significative better survival (Fig. 8).

Promising results have been published during this decade improving survival and disease free survival. This particular indication for this complex procedure represents a very promising but also conflicting tool because of the high drug Platinum sensitivity of ovarian cancer which makes medical oncologist to be confident with systemic chemotherapy results. Unfortunately despite a great number of patients optimally treated in this way a significant fraction of them relapse (50-70%) and in this case it is reasonable to think that extreme cytoreduction and HIPEC can be helpful.

6. Advanced oncological surgery in malignant peritoneal mesothelioma

Diffuse malignant peritoneal mesothelioma (DMPM) is a relatively uncommon peritoneal malignancy, representing 20-30% of 2.200-2.500 new cases diagnosed every year in USA, but its incidence has been rising worldwide since 1970s and is not expected to peak for another 5 to 20 years. The reason lays in its recognized association with asbestos exposure, which has been extensively used in the past as building material (Battifora, 1995; Robinson and Lake, 2005). Along with the occupational exposure, DMPM has been reported following radiation therapy, mica exposure, recurrent peritonitis and thorium dioxide administration (Maurer and Egloff, 1975; Antman *et al.*, 1983; Chahinian *et al.*, 1982; Riddell *et al.*, 1981).

It is characterized macroscopically by thousands of whitish tumor nodules of variable size and consistency that may coalesce to form plaques or masses that may layer out to uniformly cover the entire peritoneal surface. Traditionally, DMPM was considered a preterminal condition, as the majority of patients died from intestinal obstruction or terminal starvation within the first year from the diagnosis (Yan *et al.*, 2007). Despite its generally local spread without lymphadenopathy or distant organ metastases, its poor prognosis may be explained by late diagnosis, due to the aspecificity of presenting symptoms (abdominal pain, girth, ascitis,...) and the inadequateness of most imaging tools in detecting small nodules on the whole peritoneal surface. Furthermore, no uniform treatment was initially suggested for this kind of malignancy, systemic chemotherapy and abdominal radiation therapy showed scarce results and were used only in selected patients, and surgery had only a palliative role to resolve intestinal obstruction in urgency without any significant effect on patients prognosis (Chailleux *et al.*, 1988; Antman *et al.*, 1983; Eltabbakh *et al.*, 1999; Markman and Kelsen, 1992; Neumann *et al.*, 1999; Sridhar *et al.*, 1992; Yates *et al.*, 1997). Recently, diagnostic and therapeutic aspects of the disease have been re-evaluated as encouraging reports from several centers worldwide on a combined locoregional treatment approach that uses cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have emerged. This new treatment strategy has shown favorable prognosis and has achieved in selected patients a median survival of up to

60 months and a 5-year survival of 50% using different antituberculous sequence (Deraco *et al.*, 2006; Nonaka *et al.*, 2005; Park *et al.*, 1999; Sugarbaker *et al.*, 2003; Yan *et al.*, 2007).

Given its tendency to remain confined to the peritoneal surface, the prognosis of DMPM has been significantly improved by the combined treatment with CRS and HIPEC. In particular, while CRS reduces the tumoral mass (an optimal cytoreduction aims to residual disease smaller than 2,5mm), HIPEC maximizes loco-regional chemotherapy cytotoxicity while limiting the systemic side effects (Vlasveld *et al.*, 1991; Markman, 1990; Markman and Kelsen, 1992). In this perspective, some encouraging experiences in numerous centers demonstrated a median survival of 40 to 90 months and a 5-ys-OS of 30 to 60% (Yan *et al.*, 2007; Brigand *et al.*, 2006; Deraco *et al.*, 2006; Feldman *et al.*, 2003; Loggie *et al.*, 2001; Nonaka *et al.*, 2005; Park *et al.*, 1999; Sugarbaker *et al.*, 2003). All peritonectomy center agree that complete cytoreduction is the prognostic principal factor for clinical success and that complete cytoreduction is correlated to the initial extent of intrabdominal disease and to the ability of the surgical team. Despite the data available, the role of HIPEC in this setting represents one of the strongest indications, particularly in view of considerable survival improvement over the best systemic therapy to date offered (Munkholm-Larsen *et al.*, 2009; Shen *et al.*, 2009).

7. Advanced oncological surgery in pseudomyxoma peritonei

Appendiceal tumors are uncommon neoplasms accounting for about 1% of all colorectal malignancies.

The majority of appendix cancers are carcinoid tumors; the second most common are epithelial neoplasms. The latter frequently present with mucinous ascites and mucinous tumor implants throughout the abdominal cavity. Such rare condition, with an incidence of approximately 1/1,000,000/year, is known as pseudomyxoma peritonei (PMP). Mucinous adenocarcinoma originating from large bowel, ovary, or other intra-abdominal sites may mimic PMP (Baratti *et al.*, 2008). According to Ronnett, PMP was histologically classified into disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and intermediate or discordant feature group (ID). Appendiceal tumors were classified into low-grade appendiceal mucinous neoplasm (LAMN) and mucinous adenocarcinoma (MACA) (Misdraji). Pseudomyxoma peritonei (PMP) represents a rare peritoneal malignancy with a controversial borderline behavior. Although a possible ovarian origin was initially suggested in the female sex, the over-expression of determined molecular markers has finally demonstrated a more probable PMP origin from a perforated appendiceal epithelial tumor. Undoubtedly, a small proportion of cases originate anyway from other organs, which ovarian primary is likely to be the more commonest of, followed by colon and rectum, stomach, gallbladder and biliary ducts, small bowel, urinary bladder, lung, breast, fallopian tube and pancreas (Smeenk *et al.*, 2006, 2007; de Bree *et al.*, 2000).

PMP is clinically characterized by diffuse intra-abdominal gelatinous collections with mucinous implants on peritoneal surfaces. Its pathognomonic accumulation at specific abdominal and pelvic sites is due to the so-called phenomenon of "redistribution" within

the peritoneal cavity, which is determined by physical factors, such as the movement and absorption of peritoneal fluid and gravity (Sugarbaker, 1994). Despite its usually indolent behavior, its natural history is characterized by a slow progression to terminal starvation through intestinal obstruction by mucinous ascitis. Recent pathological (Ronnett *et al.*, 1995) molecular genetic (Szych *et al.*, 1999) and immunohistochemical studies (Carr *et al.*, 2002) have provided substantial evidence that most cases of PMP originate from ruptured low grade appendiceal tumors and that mucin-producing epithelial cells accumulate into the abdominal cavity as a result of a distribution process. Therefore, surgical management consisted in repeated interval debulking for symptomatic relief (Sugarbaker, 1996). Based on recent prospective trials, CRS and HIPEC has been proposed as the standard of care for PMP. Results are encouraging with a 5-ys-OS ranging from 62.5 to 100% for low grade PMP and from 0 to 65% for high grade disease. This differentiation is crucial for the evolution of disease; low grade tumours are slow growing and indolent differently from those high grade, fast growing and aggressive (Sugarbaker and Chang, 1999; Witkamp *et al.*, 2001; Güner *et al.*, 2005; Moran *et al.*, 2008; Moran and Cecil, 2003; Murphy *et al.*, 2007; Baratti *et al.*, 2008; Elias *et al.*, 2008; Loungnarath *et al.*, 2005; Smeenk *et al.*, 2007; Stewart *et al.*, 2005; Yan *et al.*, 2006). The goal of the surgical cytoreduction is to remove all the visible tumor by the following procedures: right subdiaphragmatic and parietal peritonectomy, left subdiaphragmatic and parietal peritonectomy, greater omentectomy with splenectomy, lesser omentectomy and stripping of the omental bursa, and pelvic peritonectomy with salpingo-oophorectomy in women. Depending on disease extent, implants on visceral serosa were removed by electrosurgical local dissection or multivisceral resections including Glisson's capsule dissection, cholecystectomy, partial or total gastrectomy, sigmoid, right or total colectomy. According to several phase I and II prospective trials, 5-year survivals have ranged between 66% and 97% (Stewart *et al.*, 2005). It must be taken in mind that, because of the limited data on prognostic factors for this procedure in the setting of appendiceal primary tumors, further well designed, prospective, multi-institutional study are required (Bevan *et al.*, 2010; Roviello *et al.*, 2011).

8. Conclusion

CRS and HIPEC is a complex therapeutic systems which require highly specialized human resources, complex technological facilities, very much depending from expertise of the team involved. Literature refers to a learning curve of more than 100 procedures underscoring the crucial importance of treatment center experience. A continuous comparison must be done with new systemic and locoregional treatment possibility in order to verify new advantages in term of patient survival. This is the reason why a biannual international meeting is planned for comparing results, verify indications and planning of further studies regard to indications, duration and temperature of the perfusion, open or closed perfusion models or type and dosage of chemotherapeutic agents.

The future of treatment of peritoneal carcinosis appears correlated to the strong cooperation with medical oncologists to select patients and focusing on the timing of treatment which in our experience is crucial. The development of new scheme treatment must be approached as in treating ovarian peritoneal carcinosis with front line, interval, or salvage procedures.

Therefore creating regional centers dedicated to peritoneal carcinosis treatment that investigate not only response and survival, but also standardization of technique and methods to do CRS and deliver HIPEC remains crucial.

Author details

Enrico Maria Pasqual and Serena Bertozzi
University of Udine, Italy

9. References

- Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. *J Clin Oncol* 1988; 6:147-153;
- Antman KH, Corson JM, Li FP, Greenberger J, Sytkowski A, Henson DE, Weinstein L. Malignant mesothelioma following radiation exposure. *J Clin Oncol* 1983;1:695-700.
- Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). *Ann Surg Oncol* 2008;15:526-534.
- Battifora H. Tumors of the serosal membranes. Armed Forces Institute of Pathology under the auspices of Universities Associated for Research and Education in Pathology, Washington, D.C, 1995.
- Bereder J, Glehen O, Habre J, Desantis M, Cotte E, Mounier N, Ray-Cocquard I, Karimjee B, Bakrin N, Bernard J, *et al.* Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: a multiinstitutional study of 246 patients. In *J Clin Oncol* (Meeting Abstracts), vol. 27. 2009; 5542.
- Bevan KE, Mohamed F, Moran BJ. Pseudomyxoma peritonei. *World J Gastrointest Oncol* 2010;2:44-50.
- Boyle P, Ferlay J. Cancer incidence and mortality in europe, 2004. *Ann Oncol* 2005;16:481-488.
- Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. *Ann Surg Oncol* 2006;13:405-412.
- Carr NJ, Emory TS, Sobin LH. Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis, and expression of p53, cd44, bcl-2. *Arch Pathol Lab Med* 2002;126:837-841.
- Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma. prospective evaluation of 69 patients. *Ann Intern Med* 1982;96:746-755.

- Chailleux E, Dabouis G, Pioche D, de Lajartre M, de Lajartre AY, Rembeaux A, Germaud P. Prognostic factors in diffuse malignant pleural mesothelioma. a study of 167 patients. *Chest* 1988;93:159–162.
- Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. a prospective study of prognostic factors. *Cancer* 1989;63:364–367.
- De Bree E, Witkamp AJ, Zoetmulder FA. Peroperative hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer. *Eur J Surg Oncol* 2000;26:630–632.
- Deraco M, Gronchi A, Mazzaferro V, Inglese MG, Pennacchioli E, Kusamura S, Rizzi M, Anselmi RA Jr, Vaglini M. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with pseudomyxoma peritonei. *Tumori* 2002;88:370–375.
- Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, Salvatore A, Cabras Ad AD, Kusamura S. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. *Ann Surg Oncol* 2006;13:229–237.
- Elias D, Honoré C, Ciuchendéa R, Billard V, Raynard B, Lo Dico R, Dromain C, Duvillard P, Goéré D. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Br J Surg* 2008;95:1164–1171.
- Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. *J Clin Oncol* 2009;27:681–685.
- Elias D, Raynard B, Farkhondeh F, Goéré D, Rouquie D, Ciuchendea R, Pocard M, Ducreux M. Peritoneal carcinomatosis of colorectal origin. *Gastroenterol Clin Biol* 2006;30:1200–1204.
- Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. *J Surg Oncol* 1999;70:6–12.
- Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. *J Clin Oncol* 2003;21:4560–4567.
- Flessner MF. The transport barrier in intraperitoneal therapy. *Am J Physiol Renal Physiol* 2005;288:F433–F442.
- Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. *Cancer* 2010;116:3756–3762.
- Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. *Cancer* 1999;85:529–534.

- Glehen O, Cotte E, Lifante JC, Arvieux C, Moles N, Brigand C, Beaujard AC, François Y, Gilly FN. Peritoneal carcinomatosis in digestive cancers: cytoreductive surgery combined with intraperitoneal chemohyperthermia. The experience in centre hospitalier et universitaire lyon sud (chls). *Acta Chir Belg* 2006;106:285–290.
- Glockzin G, Ghali N, Lang SA, Schlitt HJ, Piso P. Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. *J Surg Oncol* 2009;100:306–310.
- Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. *Cancer* 2000;89:2068–2075.
- Güner Z, Schmidt U, Dahlke MH, Schlitt HJ, Klempnauer J, Piso P. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. *Int J Colorectal Dis* 2005;20:155–160.
- Hanazaki K, Mochizuki Y, Machida T, Yokoyama S, Sodeyama H, Sode Y, Wakabayashi M, Kawamura N, Miyazaki T. Post-operative chemotherapy in non-curative gastrectomy for advanced gastric cancer. *Hepatogastroenterology* 1999;46:1238–1243.
- Issels RD. Hyperthermia adds to chemotherapy. *Eur J Cancer* 2008;44:2546–2554.
- Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. *Br J Surg* 2002;89:1545–1550.
- Koppe MJ, Boerman OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. *Ann Surg* 2006;243:212–222.
- Levine EA, Stewart JH 4th, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. *J Am Coll Surg* 2007;204:943–53; discussion 953–5.
- Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. *Am Surg* 2001;67:999–1003.
- Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. *Int J Gynecol Cancer* 2004;14:35–41.
- Loungnarath R, Causeret S, Bossard N, Faheez M, Sayag-Beaujard AC, Brigand C, Gilly F, Glehen O. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. *Dis Colon Rectum* 2005;48:1372–1379.
- Markman M. Intraperitoneal belly bath chemotherapy. Percept Press, Chicago, 2nd ed., 1990.
- Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. *J Cancer Res Clin Oncol* 1992;118:547–550.
- Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A, Folli S, Cordiano C, Pinto E, IRGfGC. Different patterns of recurrence in gastric cancer depending on lauren's histological type: longitudinal study. *World J Surg* 2002;26:1160–1165.

- Maurer R, Egloff B. Malignant peritoneal mesothelioma after cholangiography with thorotrast. *Cancer* 1975;36:1381–1385.
- Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the locoregional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). *J Surg Oncol* 2008;98:277–282.
- Moran BJ, Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei. *Surg Oncol Clin N Am* 2003;12:585–603.
- Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. *World J Gastrointest Surg* 2009;1:38–48.
- Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. *Dis Colon Rectum* 2007;50:37–42.
- Neumann V, Müller KM, Fischer M. Peritoneal mesothelioma—incidence and etiology. *Pathologie* 1999;20:169–176.
- Nonaka D, Kusamura S, Baratti D, Casali P, Cabras AD, Younan R, Rosai J, Deraco M. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. *Cancer* 2005;104:2181–2188.
- Ozols RF. Treatment goals in ovarian cancer. *Int J Gynecol Cancer* 2005;15 Suppl 1:3–11.
- Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, Bartlett DL. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (chpp). *Ann Surg Oncol* 1999;6:582–590.
- Randall TC, Rubin SC. Cytoreductive surgery for ovarian cancer. *Surg Clin North Am* 2001;81:871–883.
- Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, Younan R, Baratti D, Mariani L, Laterza B, Deraco M. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of national cancer institute of milan. *Eur J Surg Oncol* 2006;32:671–675.
- Riddell RH, Goodman MJ, Moossa AR. Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. *Cancer* 1981;48:134–139.
- Robinson BWS, Lake RA. Advances in malignant mesothelioma. *N Engl J Med* 2005;353:1591–1603.
- Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". *Am J Surg Pathol* 1995;19:1390–1408.
- Roviello F, Caruso S, Marrelli D, Pedrazzani C, Neri A, De Stefano A, Pinto E. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. *Surg Oncol* 2011;20:e38–e54.
- Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN.

- Peritoneal carcinomatosis from non-gynecologic malignancies: results of the evocape 1 multicentric prospective study. *Cancer* 2000;88:358–363.
- Sayag-Beaujard AC, Francois Y, Glehen O, Sadeghi-Looyeh B, Bienvenu J, Panteix G, Garbit F, Grandclément E, Vignal J, Gilly FN. Intraperitoneal chemo-hyperthermia with Mitomycin C for gastric cancer patients with peritoneal carcinomatosis. *Anticancer Res* 1999;19:1375–1382.
- Shen P, Stewart JH 4th, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: overview and rationale. *Curr Probl Cancer* 2009;33:125–141.
- Smeenk RM, Bex A, Verwaal VJ, Horenblas S, Zoetmulder FAN. Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications. *J Surg Oncol* 2006;93:20–23.
- Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FAN. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg* 2007;245:104–109.
- Sridhar KS, Doria R, Raub W Jr, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. *Cancer* 1992;70:2969–2979.
- Stewart JH 4th, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. *Ann Surg Oncol* 2005;12:765–777.
- Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. *Ann Surg* 1994;219:109–111.
- Sugarbaker PH. Peritonectomy procedures. *Ann Surg* 1995;221:29–42.
- Sugarbaker PH. Pseudomyxoma peritonei. *Cancer Treat Res* 1996;81:105–119.
- Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. *Ann Surg Oncol* 1999;6:727–731.
- Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at The Washington cancer institute. *Surg Oncol Clin N Am* 2003;12:605–21, xi.
- Szych C, Staebler A, Connolly DC, Wu R, Cho KR, Ronnett BM. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. *Am J Pathol* 1999;154:1849–1855.
- Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. *Cancer J* 2009;15:216–224.
- Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FAN. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol* 2003;21:3737–3743.
- Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. *Ann Surg Oncol* 2005;12:65–71.
- Vlasveld LT, Gallee MP, Rodenhuis S, Taal BG. Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. *Eur J Cancer* 1991;27:732–734.

- Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-c in patients with peritoneal carcinomatosis of colorectal origin. *Eur J Cancer* 2001;37:979–984.
- Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. *Ann Surg Oncol* 2007;14:41–49.
- Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. *Br J Surg* 2006;93:1270–1276.
- Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? *Ann Surg* 2008;248:829–835.
- Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. *Cancer* 1993;71:517–523.
- Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. *Thorax* 1997;52:507–512.
- Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, Sugiyama K, Kawamura T, Kinoshita K, Endou Y, Sasaki T. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. *Hepatogastroenterology* 2001;48:1776–1782.
- Yonemura Y, Fujimura T, Nishimura G, FallaR, Sawa T, Katayama K, Tsugawa K, Fushida S, Miyazaki I, Tanaka M, Endou Y, Sasaki T. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. *Surgery* 1996;119:437–444.